PA8715601A1 - Modulacion de la formacion de huesos - Google Patents

Modulacion de la formacion de huesos

Info

Publication number
PA8715601A1
PA8715601A1 PA20078715601A PA8715601A PA8715601A1 PA 8715601 A1 PA8715601 A1 PA 8715601A1 PA 20078715601 A PA20078715601 A PA 20078715601A PA 8715601 A PA8715601 A PA 8715601A PA 8715601 A1 PA8715601 A1 PA 8715601A1
Authority
PA
Panama
Prior art keywords
ror2
modulation
produce
protein
activity
Prior art date
Application number
PA20078715601A
Other languages
English (en)
Spanish (es)
Inventor
Billiard Julia
Liu Yan
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PA8715601A1 publication Critical patent/PA8715601A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/10Musculoskeletal or connective tissue disorders
    • G01N2800/108Osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PA20078715601A 2006-02-17 2007-02-16 Modulacion de la formacion de huesos PA8715601A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77453406P 2006-02-17 2006-02-17
US84423906P 2006-09-13 2006-09-13

Publications (1)

Publication Number Publication Date
PA8715601A1 true PA8715601A1 (es) 2008-11-19

Family

ID=38437973

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20078715601A PA8715601A1 (es) 2006-02-17 2007-02-16 Modulacion de la formacion de huesos

Country Status (19)

Country Link
US (1) US20090047287A1 (https=)
EP (1) EP1984395A2 (https=)
JP (1) JP2009527485A (https=)
KR (1) KR20080095269A (https=)
AR (1) AR060104A1 (https=)
AU (1) AU2007217779A1 (https=)
BR (1) BRPI0707864A2 (https=)
CA (1) CA2638803A1 (https=)
CR (1) CR10212A (https=)
EC (1) ECSP088682A (https=)
IL (1) IL193271A0 (https=)
MX (1) MX2008010511A (https=)
NO (1) NO20083497L (https=)
PA (1) PA8715601A1 (https=)
PE (1) PE20071309A1 (https=)
RU (1) RU2008131052A (https=)
SV (1) SV2009002997A (https=)
TW (1) TW200800266A (https=)
WO (1) WO2007098198A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2566886A1 (en) * 2010-05-05 2013-03-13 Addex Pharma SA Methods and tools for screening agents exhibiting an activity on receptors of the tumor necrosis factor receptor superfamily
WO2013070033A1 (ko) * 2011-11-09 2013-05-16 주식회사 아이엠헬스케어 골다공증 및 골회전율 진단 스트립
KR101354826B1 (ko) * 2011-12-08 2014-01-27 아주대학교산학협력단 중간엽줄기세포 렙틴분비능을 이용한 골다공증 예방 또는 치료용 물질 스크리닝 방법
US20140322234A1 (en) * 2012-01-03 2014-10-30 The Board Of Trustees Of The Leland Stanford Junior University Analysis and Targeting of ROR2 in Cancer
JP6463029B2 (ja) * 2013-08-02 2019-01-30 有未 伊谷 ヒト間葉系幹細胞を特異的に認識するモノクローナル抗体並びにこれを用いたヒト間葉系幹細胞の分離及び/または品質評価を行う方法
ES2927112T3 (es) * 2014-08-01 2022-11-02 Purec Co Ltd Método para evaluar la calidad de células madre mesenquimatosas humanas y un anticuerpo monoclonal para su uso en dicho método
JP7057557B2 (ja) * 2015-07-31 2022-04-20 国立大学法人大阪大学 上皮疾患に対する治療及び/又は予防有効性を評価する方法、上皮疾患治療剤のスクリーニング方法、及び上皮疾患治療剤
CN116751298A (zh) 2016-05-13 2023-09-15 生物蛋白有限公司 抗ror2抗体、抗体片段和它们的免疫缀合物以及其用途
GB201718985D0 (en) 2017-11-16 2018-01-03 Univ London Queen Mary Treatment
US11793452B2 (en) 2019-10-03 2023-10-24 Johnson & Johnson Consumer Inc. Method of visualizing and quantifying remineralization
CN115786252B (zh) * 2023-02-07 2023-05-05 赛德特生物制药有限公司 人脐带间充质干细胞成骨诱导分化培养基及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312814A (en) * 1992-12-09 1994-05-17 Bristol-Myers Squibb Co. α-phosphonocarboxylate squalene synthetase inhibitors
AU2001238571A1 (en) * 2000-03-14 2001-09-24 Regeneron Pharmaceuticals, Inc. Methods of stimulating cartilage formation
EP1603586A1 (en) * 2003-02-19 2005-12-14 Aziz Ghahary 14-3-3 protein for prevention and treatment of fibroproliferative disorders
AU2004233060A1 (en) * 2003-04-16 2004-11-04 Wyeth A novel method of modulating bone-realted activity

Also Published As

Publication number Publication date
JP2009527485A (ja) 2009-07-30
CR10212A (es) 2008-10-03
NO20083497L (no) 2008-10-31
BRPI0707864A2 (pt) 2011-05-10
RU2008131052A (ru) 2010-03-27
ECSP088682A (es) 2008-09-29
US20090047287A1 (en) 2009-02-19
KR20080095269A (ko) 2008-10-28
MX2008010511A (es) 2008-11-18
AR060104A1 (es) 2008-05-28
TW200800266A (en) 2008-01-01
IL193271A0 (en) 2011-08-01
SV2009002997A (es) 2009-04-17
WO2007098198A3 (en) 2008-03-13
WO2007098198A2 (en) 2007-08-30
AU2007217779A1 (en) 2007-08-30
EP1984395A2 (en) 2008-10-29
CA2638803A1 (en) 2007-08-30
PE20071309A1 (es) 2008-02-13

Similar Documents

Publication Publication Date Title
PA8715601A1 (es) Modulacion de la formacion de huesos
CY1123580T1 (el) Συντετμημενες πρωτεϊνες συγχωνευσης actriib-fc
GT200600316A (es) Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
MX2020004712A (es) Vesiculas extracelulares modificadas geneticamente con proteinas.
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
CY1119127T1 (el) Επιτοποι σκληροστινης
CR9942A (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
ATE539089T1 (de) Cyclische rezeptor-assoziierte-proteine (rap)- peptide
CL2012003293A1 (es) Compuestos derivados de aminopirimidina, como moduladores de la proteina quinasa rica en repeticiones leucina 2 (lrrk2); composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de parkinson.
GT201200271A (es) Proteínas que se unen al tnf-a
BR112019018307A2 (pt) Plataforma para identificação de peptídeos imunogênicos baseada em população
CY1115588T1 (el) Αναστολεις ανθρωπινης πρωτεϊνικης φωσφατασης τυροσινης-β και η φαρμακευτικη χρηση τους
ECSP077316A (es) Compuestos imidazo-3-il-amina bicíclicos sustituidos
UY31073A1 (es) Inhibidores de la proteína activadora de la 5-lipoxigenasa (flap)
CY1114887T1 (el) Συνθεσεις και μεθοδοι παρασκευης συνθεσης
PH12019501319A1 (en) Gremlin-1 crystal structure and inhibitory antibody
EA201291180A1 (ru) Композиции и способы применения терапевтических антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
CU23978B1 (es) Composiciones para anticuerpos que se dirigen a la proteína de complemento c5
UY31478A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo
CY1113199T1 (el) Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης
MX2009007688A (es) Gel de fibrina para liberacion controlada de tgp-beta y usos del mismo.
CL2010001569A1 (es) Pestivirus atenuado mediante la mutacion conjunta de las proteinas e erns y n pro.composicion inmunogenica y vacuna que lo comprende, metodo para atenuar pestivirus basado en la supresion de la dimerizacion de la proteina e rns y la ianactivacion de la proteina n pro.
BR112016000565A2 (pt) polipeptídeo cíclico, derivado ou análogo do mesmo e seu uso modulador alostérico, composição farmacêutica, processo para produzir a mesma
CR11562A (es) Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina
CL2012001380A1 (es) Composición farmacéutica o cosmética que comprende el polipéptido coriolisina l, las proteínas muy ácidas vapi, vapii, vapiii, y una o más moléculas de ácido nucleico que codifican cualquiera de los polipéptidos recién mencionados; ácido nucleico; vector, célula hospedera; método de preparación de dichos polipéptidos; y método cosmético para exfoliar y/o humectar la piel de un animal.